Achieving a better cure for cancer

CiMaas receives a new grant from LIOF to further explore the recently developed and patented feeder cell technology. A GMP grade feeder cells master bank has been previously generated and serves as starting material.

Previously we have seen identical expansion rates and cytotoxicity of the expanded NK cells, and within this grant we will more extensively validate the NK cell expansion, activation and functional characteristics in comparison to the original protocol in which irradiation technology was used. 

Finally with in the grant we will validate all characteristics in large-scale NK cell batches with numbers ready for clinical applications in cancer.

As of today, CiMaas is located at the Schleperweg 36, in Maastricht (NL). In this facility we continue our work on (GMP grade) feeder cells and NK cell technology for the benefit of cancer patients.

Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our activities will be realized in Maastricht.